Caris
Caris, Sorrento, Prostate Cancer Clinical Trial Consortium Ink Clinical Trial Partnership
The partners will use Caris' MI Profile to analyze samples from metastatic castration-resistant prostate cancer patients in Sorrento's Phase II Maverick trial.
In Brief This Week:Â OncoHost, Matica Biotechnology, Xilis, Aptose Biosciences, Cigna
News items for the week of May 2, 2022.
In Brief This Week: Artemis DNA, ITM Isotope Technologies, BriaCell, Caris Life Sciences
News items for the week of April 11, 2022.
Zentalis Pharmaceuticals, Caris Life Sciences Ink Precision Oncology Partnership
Caris will use its platform to sequence solid tumor patients' full exomes and transcriptomes to determine eligibility for Zentalis' Wee1 inhibitor ZN-c3.
Caris Life Sciences to Help ID Patients for Pyramid Biosciences' Cancer Drug Study
The companies will use Caris' sequencing platform and clinical trial solution to identify patients with NTRK fusion-driven cancers.
May 19, 2021